It’s “a move away from a one-size-fits-all framework for Alzheimer’s disease.” ...

A new study from Mass General Brigham suggests a blood test may detect early biological signs of Alzheimer’s disease earlier ...

Autism and Alzheimer’s disease have long occupied separate corners of neuroscience. One is diagnosed in childhood; the other emerges late in life. But a convergence of epidemiological data, genetic ...

Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.

New research suggests that tubulin may help prevent the toxic protein clumps associated with Alzheimer’s and Parkinson’s diseases.

Alzheimer’s “wonder drugs” do not work, scientists have found in a study that overturns decades of research into the disease.

A systematic review suggested that drugs targeting amyloid beta appeared to have no clinically meaningful positive effects, ...

Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major ...

Alzheimer's Society responds to the claim that amyloid-targeting drugs show no clinically meaningful positive effects.

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, ...

Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing ...

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.